Orthopedic hip surgery is associated with considerable blood loss and high rates of perioperative transfusion.[@B1] A recent meta-analysis of 19 studies showed that 24% of patients undergoing total hip replacement or total knee replacement and 44% of those with hip fracture had preoperative anemia. It has also been reported that more than 50% of such patients became anemic after surgery due to intraoperative blood loss.[@B2][@B3] Allogenic red blood cell transfusion is frequently used to treat acute postoperative anemia, and 20%--50% of these patients receive at least one unit of red blood cells.[@B3][@B4]

However, transfusions prolong the length of hospital stay and increase in-patient costs, the risks of hematogenic infections, and mortality after orthopedic procedures.[@B5][@B6][@B7] Furthermore, these complications may involve morbidity or mortality, which makes the development of blood-saving strategies a necessity.[@B8][@B9] In this respect, the three-pillar concept of patient blood management was developed to reduce the risk of transfusion.[@B10][@B11]

In addition to perioperative blood loss, iron homeostasis can result in postoperative anemia through a condition called functional iron deficiency, which is caused by the sequestration of iron in macrophages due to the deactivation of ferroportin by inflammatory cytokines.[@B12][@B13] Accordingly, iron replacement strategies for correcting preoperative anemia have been widely studied.[@B14]

The routine use of oral ferrous sulphate after total hip and knee arthroplasty is not recommended because of its side effects.[@B14] On the other hand, parenteral ferric carboxymaltose is a safe and effective treatment option with the advantages of lower risks of gastrointestinal side effects.[@B15][@B16][@B17][@B18] Although intravenous ferric carboxymaltose (IV-FCM) has been demonstrated to increase hemoglobin levels in preoperative orthopedic surgical patients, no clear role has been established for postoperative iron supplementation.[@B14][@B19][@B20]

Hence, we postulated that postoperative IV-FCM might reduce the amount of transfusion after orthopedic hip surgery without adverse influences on clinical outcomes. This study was undertaken to determine whether postoperative IV-FCM would reduce the amount of transfusion without influencing clinical outcomes in patients that have undergone hip surgery.

METHODS
=======

All procedures involving human participants were performed in accordance with the ethical standards of Institutional Review Board of Seoul National University Hospital (IRB No. 1612-008-810) and with the Helsinki Declaration (1964) and its later amendments. Written informed consent was obtained from all patients before surgical treatment and patients also consented to the use of their data in future publications.

We adopted a new perioperative blood management protocol for patients that undergo orthopedic hip surgery in May 2014 that involves postoperative screening by blood testing immediately after surgery. Patients meeting the following criteria were administered 1 g of ferric carboxymaltose intravenously (2 vials of Ferinject; Vifor France SA, Puteaux, France). The criteria used were (1) an immediate postoperative hemoglobin concentration of \< 10 g/dL or (2) a hemoglobin concentration fall of \> 3 g/dL versus the preoperative value. According to this protocol, 150 of 846 patients were intravenously injected with ferric carboxymaltose postoperatively between May 2014 and April 2016, and these 150 patients were enrolled in the present study. In addition to this IV-FCM protocol, we adopted a strict transfusion protocol, which triggered transfusion when hemoglobin concentrations fell below 8 g/dL or symptoms of acute anemia (e.g., dizziness, chest pain, tachycardia, and persistent hypotension) occurred.

A biostatistician performed one-to-one matching with patients that underwent hip surgery before the introduction of the new protocol using the propensity scoring method. Variables included for the propensity score matching were sex, age, initial diagnosis, and type of hip surgery. After propensity score matching, all variables were successfully matched ([Table 1](#T1){ref-type="table"}). Finally, the data of 300 patients (IV-FCM group, n = 150; control group, n = 150) were included in the analysis. In both groups, there were 43 men and 107 women with ages ranging from 20 to 91 years. The most common diagnosis in both groups was osteonecrosis of the femoral head (39%), followed by femur neck fracture (15%), degenerative arthritis (13%), intertrochanteric fracture (11%) and dysplastic hip (7%) ([Table 1](#T1){ref-type="table"}).

Intermittent pneumatic compression devices and low-dose aspirin (100 mg qd) were used for venous thromboembolism prophylaxis and negative pressure blood drainage was applied for 2--3 days in all patients after surgery.

Clinical data were collected retrospectively from medical records. In particular, medical and drug histories were checked for items that might affect bleeding or thromboembolic tendency, such as histories of cerebral infarction, coronary artery disease, or valvular heart disease and the use of antiplatelet or anticoagulant medication. Perioperative blood losses were evaluated, and we checked whether transfusion was performed postoperatively. Perioperative blood loss was defined as the sum of estimated blood loss during surgery and postoperative drainage amount through the negative pressure drainage system. Postoperative transfusion amounts were also evaluated. Blood hemoglobin concentrations were measured at 1 and 6 weeks after surgery and compared to values obtained preoperatively and immediately after surgery. Hospital stay (defined as the number of days spent in hospital from the day of surgery until discharge) and postsurgical complications were noted, as were periprosthetic joint infection, urinary tract infections, respiratory infections, and venous thromboembolism during admission. Infection was defined as a positive bacterial culture and the need for antibiotics. Adverse effects of IV-FCM associated drug reactions, such as hypersensitivity and infusion site reactions, were noted by nurses administering IV-FCM. Patients were monitored during admission and any cardiovascular event, infection, or other adverse drug reaction requiring intervention was evaluated.

The primary study variables were perioperative blood loss, number of blood units transfused, and changes in hemoglobin concentrations at 1 week and 6 weeks after surgery. The secondary variables were duration of hospital stay and the prevalence of IV-FCM-associated postsurgical complications and adverse drug reactions. Statistical analysis was performed using the Student *t*-test in SPSS ver. 23.0 (IBM Corp., Armonk, NY, USA). Statistical significance was accepted for *p*-values of \< 0.05.

RESULTS
=======

Average amounts of perioperative blood loss in the two groups were not significantly different (*p* = 0.143). Ninety-two patients (61%) were transfused in the control group and 70 patients (47%) were transfused in the IV-FCM group. Furthermore, the average number of transfused blood units was significantly lower in the IV-FCM group (1.7 ± 2.7 vs. 1.0 ± 1.2 units, *p* = 0.002) ([Table 2](#T2){ref-type="table"}).

Preoperative hemoglobin concentrations were similar in the two groups. In both groups, average postoperative hemoglobin concentrations were significantly lower than preoperative concentrations. Moreover, the average hemoglobin concentration was significantly lower in the IV-FCM group immediately after surgery and 1 week after surgery than the average concentration before surgery (baseline). At 6 weeks after surgery, average hemoglobin concentrations recovered to baseline in both groups. However, at 6 weeks after surgery, the average hemoglobin concentration was significantly higher in the IV-FCM group than in the control group (12.5 vs. 12.1 g/dL) ([Fig. 1](#F1){ref-type="fig"}). When average hemoglobin concentrations at 6 weeks after surgery were compared with those measured preoperatively, immediate after surgery, and at 1 week after surgery, the amount of recovered hemoglobin concentration at 6 weeks was significantly greater in the IV-FCM group than in the control group at all intervals ([Fig. 2](#F2){ref-type="fig"}).

The average hospital stay was significantly shorter in the IV-FCM group than in the control group (7.6 days vs. 11.8 days). However, the prevalence of postsurgical complications, including periprosthetic joint infections, urinary tract and upper respiratory infections, and venous thromboembolism were similar in the two groups ([Table 2](#T2){ref-type="table"}). No adverse drug reaction previously reported to be a possible side effect of FCM, such as hypersensitivity, cardiovascular event or infusion site reaction, was observed.[@B21][@B22][@B23]

DISCUSSION
==========

This study was undertaken to determine whether IV-FCM administered immediately after surgery could reduce transfusion frequency and amounts and significantly increase hemoglobin levels after hip surgery. The IV-FCM group was found to have transfusions less frequently and to have been transfused with smaller amounts than the control group (61% vs. 47% and 1.7 ± 2.7 vs. 1.0 ± 1.2 units, respectively). Furthermore, hemoglobin concentration recovery was greater in the IV-FCM group at 6 weeks postoperatively. Finally, IV-FCM was not found to affect surgery-associated complications or adverse drug reactions.

Blood loss is not the only factor that can influence iron status. Inflammatory cytokines, such as interleukins and tumor necrosis factor-alpha (TNF-α), that are released after hip surgery affect iron homeostasis, as these cytokines lead to iron uptake by activated macrophages. Accordingly, surgery per se may cause changes in iron metabolism, that is, a decrease in serum levels of iron and transferrin and an increase in serum ferritin concentration.[@B12] In this respect, IV-FCM may confer benefits by directly supplementing hemoglobin levels and inhibiting the formation of TNF-α.[@B13]

The average amount of perioperative blood loss was not different in our two study groups (*p* = 0.143), but IV-FCM reduced transfusion frequency and amounts. This result may have been due to the adoption of a strict transfusion protocol. In particular, although IV-FCM is not a substitute for blood products, IV-FCM was administered instead of routine blood transfusion, and thus, indiscriminate transfusions were probably reduced.

Average hemoglobin concentrations were significantly lower in the IV-FCM group immediately after and 1 week after surgery, which was probably associated with the indications for IV-FCM used. Nevertheless, the amount of recovered hemoglobin concentration at 6 weeks was significantly greater in the IV-FCM group than in the control group at every time interval.

Furthermore, the average hospital stay was significantly shorter in the IV-FCM group than in the control group (7.6 vs. 11.8 days), and it is not reasonable to ascribe this to IV-FCM. During recent years, we have promoted early ambulation and rehabilitation programs, and thus, have shortened hospital stays after hip surgeries. Accordingly, we believe this result was not due to IV-FCM but due to postoperative care protocol changes. Nevertheless, the prevalence of postsurgical complications, such as periprosthetic joint infections, urinary tract and upper respiratory infections and venous thromboembolism were not different in the two groups.

IV iron supplementation raises several concerns. The first is life-threatening hypersensitivity;[@B23] others include cardiovascular events and infections.[@B8][@B21][@B22] In the present study, we encountered no adverse drug reaction, such as hypersensitivity, a cardiovascular event, or an infusion site reaction. These results concur with the previous findings of a systematic review of 10,390 patients that participated in 103 trials, in which it was concluded intravenous iron supplementation is not associated with increased risks of adverse drug reactions or infections.[@B24]

Few studies have investigated the effects of postoperative intravenous iron supplementation on blood transfusion requirements or on the recoveries of hemoglobin concentrations.[@B25][@B26][@B27] Nevertheless, our findings concur with these previous findings regarding significant reduction in blood transfusion frequency and more rapid recovery of postoperative hemoglobin concentrations after IV-FCM. The results of the present study suggest that postoperative IV-FCM administration confers benefits after diverse surgical procedures including general orthopedic hip surgery procedures and arthroplasty.

However, our study has several limitations. First, we matched patients using four criteria, that is sex, age, diagnosis, and type of hip surgery, and it is believed that other criteria can also affect clinical outcomes, such as comorbidities and medication history. We checked whether patients had a history of cerebral infarction, coronary artery disease, or valvular heart disease and whether they use antiplatelets, including aspirin, or anticoagulants, such as clopidogrel or warfarin. Nine of the 150 patients in the IV-FCM group and 19 of 150 patients in the control group (6% vs 12.7%) were found to have such a history. However, we believe comorbidities and medications were not powerful confounding factors because the average perioperative blood loss was not significantly different in the two groups. Second, IV-FCM effectively reduced transfusion and enhanced postoperative hemoglobin recovery rates. However, IV-FCM does not directly increase hemoglobin concentration like transfusion, but indirectly increases its concentration by promoting hemoglobin synthesis. Iron supplementation could improve hemoglobin synthesis and facilitate the correction of anemia, and thus, variables like serum iron, transferrin, and ferritin levels should have been considered when evaluating the iron status. Third, we evaluated the effects of FCM which is more expensive than other forms of iron supplementation like ferric hydroxide sucrose. Although ferric hydroxide sucrose (Venoferrum) is cheaper than Ferinject, it is difficult to fulfill insurance guidelines on the use of ferric hydroxide sucrose. Finally, there is a concern of administration of IV-FCM in geriatric patients, taking into account their poor hematopoietic functions compared to younger patients. However, our study concurs with the previous report showing that administration of FCM in geriatric patients is an effective treatment option for the treatment of functional iron deficiency.[@B28]

Our retrospective results show that postoperative IV-FCM reduces transfusion amounts without influencing clinical outcomes in patients that had undergone hip surgery. A blood management strategy based on postoperative IV-FCM may be beneficial for such patients. Randomized trials are required to determine whether the described blood management program is worthwhile.
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###### Baseline Characteristics of the Study Subjects

![](cios-10-20-i001)

  Variable                                                                Control group (n = 150)   IV-FCM group (n = 150)
  ----------------------------------------------------------------------- ------------------------- ------------------------
  Sex (male:female)                                                       43:107                    43:107
  Age (yr)                                                                63.6 ± 15.7               63.4 ± 15.9
  Diagnosis (no. of hips)                                                                           
   Osteonecrosis of femoral head                                          58 (39)                   
   Femur neck fracture                                                    22 (15)                   
   Degenerative arthritis                                                 20 (13)                   
   Intertrochanteric fracture                                             17 (11)                   
   Dysplasia                                                              11 (7)                    
   Miscellaneous (bearing surface wear, periprosthetic joint infection)   22 (15)                   
  Surgery                                                                                           
   THA                                                                    95 (47)                   
   Bipolar hemiarthroplasty                                               21 (18)                   
   Intramedullary nailing                                                 15 (16)                   
   Revisional THA                                                         12 (14)                   
   Open reduction and internal fixation                                   7 (5)                     

Values are presented as mean ± standard deviation or number (%).

IV-FCM: intravenous ferric carboxymaltose, THA: total hip arthroplasty.

###### Postoperative Clinical Outcomes in the Two Study Groups

![](cios-10-20-i002)

  Variable                                          Control group   IV-FCM group   *p*-value
  ------------------------------------------------- --------------- -------------- -----------
  Perioperative blood loss (mL)                     815 ± 666       915 ± 508      0.143
  No. of patients transfused                        92 (61)         70 (47)        NA
  No. of units transfused (pack)                    1.7 ± 2.7       1.0 ± 1.2      0.002^\*^
  Length of hospital stay (day)                     11.8 ± 10.3     7.6 ± 3.3      0^\*^
  Follow-up period (mo)                             33.3 ± 23.4     20.7 ± 12.0    0^\*^
  Postsurgical complication                         6 (3)           7 (4)          NA
   Periprosthetic joint infection                   1               1              NA
   Urinary tract and upper respiratory infections   5               4              NA
   Venous thromboembolism                           0               2              NA

Values are presented as mean ± standard deviation or number (%).

IV-FCM: intravenous ferric carboxymaltose, NA: not significant.

^\*^*p*-value \< 0.05.
